Antidepressant Sexual Side Effects

Home > Depression > Antidepressant Sexual Side Effects

Sexual dysfunction occurred in 59.1% of 1,022 outpatients taking antidepressants when a Spanish research group asked each patient directly with a structured questionnaire between 1995 and 2000 (Montejo and colleagues, Journal of Clinical Psychiatry, 2001). Rates for the SSRIs and venlafaxine ran from 58% to 73%; mirtazapine came in at 24.4%.

Those figures are higher than anything in a drug label, and the gap likely reflects how the question gets asked. When the same group published a second study of 2,144 outpatients in 2019, 79% met criteria for sexual dysfunction, yet only 41% had reported it without being asked (Montejo and colleagues, Archives of Sexual Behavior, 2019). The problem is common, under-reported, and usually manageable without abandoning an antidepressant that works.

SSRIs and venlafaxine carry the highest rates, bupropion the lowest

A 2009 meta-analysis restricted to studies that measured sexual function on purpose, through direct questioning or a validated scale, found treatment-emergent sexual dysfunction in 25.8% to 80.3% of patients across the serotonergic antidepressants (Serretti and Chiesa, Journal of Clinical Psychopharmacology, 2009). In decreasing order of impact the list ran sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, duloxetine, escitalopram, and fluvoxamine. Bupropion, mirtazapine, nefazodone, agomelatine, and moclobemide did not differ from placebo.

Among 6,297 adults on antidepressant monotherapy across 1,101 US primary care clinics, bupropion carried the lowest prevalence (22% to 25%), while the SSRIs, venlafaxine XR, and mirtazapine clustered between 36% and 43% (Clayton and colleagues, Journal of Clinical Psychiatry, 2002). In a subgroup without other risk factors, the odds of dysfunction were four to six times higher with an SSRI or venlafaxine XR than with bupropion SR.

Ranking the SSRIs against one another is harder. A network meta-analysis of 63 studies and more than 26,000 patients confirmed lower risk with bupropion and higher risk with escitalopram and paroxetine, yet rated the evidence as low certainty because the credible intervals were wide (Reichenpfader and colleagues, Drug Safety, 2014). Vortioxetine sits with the lower-risk agents so far: in pooled data from seven short-term manufacturer trials, its rates did not differ significantly from placebo, while duloxetine 60 mg did (Jacobsen and colleagues, CNS Spectrums, 2016).

Finally, depression itself blunts desire and arousal, so some dysfunction attributed to a drug was present before the first dose. That is why I ask at the initial evaluation.

Most patients will not mention it unless asked

In the 2019 Spanish study, 838 of 2,066 evaluable patients, or 41%, had spontaneously reported their sexual dysfunction. The rest had it and said nothing. Among those affected, 22% tolerated the problem poorly, more often men (Montejo and colleagues, 2019). Prescribers miss it as often as patients withhold it: physicians in the US primary care study consistently underestimated the prevalence (Clayton and colleagues, 2002), and the 2009 meta-analysis excluded spontaneous-report studies because patients "if not directly questioned, tend to scarcely report them."

Patients put the reluctance plainly: "Why would I bring this up when the pill is finally working?" The answer is that unspoken sexual side effects frequently lead people to stop an antidepressant, often without telling anyone (Nurnberg and colleagues, JAMA, 2003). An unannounced stop carries relapse risk and, with shorter-acting drugs, discontinuation symptoms. Raising the problem opens up the options below. Staying silent closes them.

I ask at every medication follow-up with the same two or three questions so answers can be compared. With adolescents, who are even less likely to volunteer the information, the questions are age-appropriate and asked privately (see the adolescent psychiatry page).

Waiting, lowering the dose, and drug holidays

When Spanish psychiatrists were asked what they actually did, the two most frequent strategies were switching antidepressants (34%) and waiting for spontaneous resolution (33%) (Montejo and colleagues, 2019). Waiting is reasonable for the first several weeks. However, the authors of the largest switching trial summarized the longer-term literature bluntly: antidepressant sexual dysfunction "does not resolve in most patients" (Jacobsen and colleagues, Journal of Sexual Medicine, 2015). Waiting indefinitely is usually waiting for nothing.

Dose reduction is the next step, and the one with the least trial evidence. The 2013 Cochrane review of 23 randomized trials covering 1,886 people found none testing dose reduction, drug holidays, or switching to currently available lower-risk agents (Taylor and colleagues, Cochrane Database of Systematic Reviews, 2013). Prescribers try it anyway, because the side effect appears to be dose-dependent. A lower dose may be a less effective dose, so I lower one only when the depression has been stable for months, and I track mood with the same rating scale at each visit.

Drug holidays rest on a single open study: 30 outpatients with SSRI-induced sexual dysfunction skipped their medication from Thursday morning until Sunday noon on four weekends (Rothschild, American Journal of Psychiatry, 1995). Patients on sertraline and paroxetine reported improved sexual function; those on fluoxetine, which clears far more slowly, reported none. Two of the 30 saw depression scores climb from the 4 to 8 range into the 10 to 14 range.

That study explains why holidays stay rare. Drugs short-acting enough to respond to a 3-day break may produce discontinuation symptoms when a dose is skipped, scheduling intimacy around a dosing calendar is its own problem, and the approach teaches intermittent dosing, the habit a prescriber most wants to avoid. I use it almost never.

Switching to bupropion, vortioxetine, or mirtazapine

Bupropion. A pooled analysis of seven randomized trials compared bupropion (732 patients) with sertraline, fluoxetine, or paroxetine (731 patients). Response rates were 62% versus 63% and remission 47% versus 47%, while the SSRIs produced significantly more sexual side effects than bupropion or placebo, and bupropion no more than placebo (Thase and colleagues, Journal of Clinical Psychiatry, 2005). Equal efficacy with fewer sexual side effects is the case for the switch.

The FDA label for bupropion XL gives a starting dose of 150 mg once daily, a usual target of 300 mg after four days, and a ceiling of 450 mg because seizure risk is dose-related; it also warns that bupropion can raise blood pressure. When the SSRI was also treating generalized anxiety or panic disorder, I weigh what it was doing beyond mood before moving away from a serotonergic drug.

Vortioxetine. The best switching trial to date randomized 447 adults whose depression was well controlled on citalopram, paroxetine, or sertraline, and who had treatment-emergent sexual dysfunction, to switch to either vortioxetine or escitalopram for eight weeks (Jacobsen and colleagues, 2015). Sexual functioning improved in both arms, with a larger gain on vortioxetine (8.8 versus 6.6 points on the CSFQ-14, p = 0.013), and depression control held. Notably, the escitalopram arm also improved, which likely reflects expectation and the act of changing drugs. The manufacturer ran the trial.

Mirtazapine. Mirtazapine did not differ from placebo in the 2009 meta-analysis, though the US primary care data placed it with the SSRIs. Its trade-offs in sedation and weight suit some patients and rule it out for others.

Switching carries a cost no trial captures well: a remission earned over months can slip during the crossover, so for hard-to-treat depression I often prefer augmentation. The treatment-resistant depression page covers the sequencing, and the medication management page describes how I monitor any change.

Adding bupropion to the antidepressant that works

Augmentation keeps the drug that produced remission and adds bupropion, the best-studied antidote. In a placebo-controlled trial of 42 patients with SSRI-induced sexual dysfunction, bupropion SR 150 mg twice daily for four weeks did not significantly improve the total sexual functioning score, yet it did significantly increase self-reported desire and frequency of sexual activity (Clayton and colleagues, Journal of Clinical Psychiatry, 2004).

The Cochrane review pooled three trials of bupropion 150 mg twice daily and found a large benefit over placebo on rating-scale scores (standardized mean difference 1.60), while two trials of 150 mg once daily showed no significant effect (Taylor and colleagues, 2013). The pattern looks dose-dependent, and the reviewers judged higher-dose bupropion the most promising strategy so far for women. The limitations are small trials, short duration, and subscale outcomes that may inflate effects.

In practice this is often my first pharmacological move for a patient in solid remission, particularly with residual low energy or poor concentration. The combination is off-label for sexual dysfunction, and the same seizure and blood pressure considerations apply.

PDE5 inhibitors help men; the evidence in women is thinner

For men whose main complaint is erectile dysfunction, sildenafil has the strongest single trial in this field. Ninety men with depression in remission and sexual dysfunction attributed to a serotonin reuptake inhibitor took sildenafil (50 mg, adjustable to 100 mg) or placebo for six weeks. At the end, 54.5% of the sildenafil group were much or very much improved compared with 4.4% on placebo, and depression stayed in remission in both groups (Nurnberg and colleagues, JAMA, 2003).

The Cochrane review pooled three sildenafil trials (255 men) and one tadalafil trial (54 men), found both improved erectile function more than placebo, and called the addition of a PDE5 inhibitor "an effective strategy" for men (Taylor and colleagues, 2013). The use is off-label and requires the usual cardiovascular and drug-interaction screening. Erectile dysfunction also has vascular and hormonal causes, so a medical workup is warranted when symptoms persist.

In women the picture is less settled. A trial of 98 premenopausal women found a modest advantage for sildenafil over placebo on a clinician-rated scale (mean difference 0.8 points), with 22% discontinuing early (Nurnberg and colleagues, JAMA, 2008). The Cochrane reviewers judged the benefit in women uncertain.

Post-SSRI sexual dysfunction is reported, and poorly quantified

Most antidepressant sexual side effects stop when the drug stops. A minority of patients report that they do not. Post-SSRI sexual dysfunction (PSSD) describes symptoms persisting after discontinuation, most often reduced genital sensation, weak or pleasureless orgasm, and loss of desire (Reisman, Sexual Medicine Reviews, 2017). A second review concluded that prevalence is unknown, diagnosis rests on excluding other causes, and no treatment has established efficacy (Bala and colleagues, Sexual Medicine Reviews, 2018).

The largest case series drew on RxISK, a public adverse-event reporting website, and described 300 cases of enduring sexual dysfunction from 37 countries following 14 drugs, among them serotonin reuptake inhibitors, 5-alpha-reductase inhibitors, and isotretinoin (Healy and colleagues, International Journal of Risk and Safety in Medicine, 2018). In May 2019 the European Medicines Agency's safety committee required every SSRI and SNRI label in the European Union to add: "There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI."

This literature has several limitations. First, the cases are self-reported without a denominator, so no rate can be calculated. Second, depression and anxiety themselves impair sexual function and can recur after a drug is stopped. Third, there are no controlled studies. Nevertheless, two independent reviews and a regulator have concluded that the entity exists. I tell patients starting an SSRI that persistent dysfunction has been reported, that its frequency is unknown, and that ordinary side effects are far more common and usually reversible.

How to raise it with your prescriber

Bring it to a scheduled visit rather than a refill request, with four pieces of information: which phase is affected (desire, arousal, or orgasm); when it started relative to the medication and whether it predated it; what dose you're on and whether anything else changed, including alcohol or other medications; and what you're willing to trade, since a patient protecting a marriage needs a different plan than one who wants no risk to a hard-won remission.

A prescriber who hears this should offer options from the list above, explain the evidence, and set a date to reassess. Decisions about dose, switching, and add-on medication are individual and belong with the prescriber; what you shouldn't do is stop on your own. If the answer is "that's just part of taking the medication," a second opinion is reasonable. For milder depression, psychotherapy alone sidesteps the problem (see medication versus therapy).

Who this practice fits, and when to go elsewhere

This fits adults and adolescents whose antidepressant is working and who have sexual side effects they haven't raised, or raised and were told to live with. It fits people quietly planning to stop because of this, and people who stopped and have symptoms that persist. The depression treatment page describes how the practice approaches the underlying illness.

Some situations belong elsewhere first. Men with erectile dysfunction and cardiovascular risk factors need primary care or urology before any PDE5 inhibitor. Pain during intercourse points toward other causes and needs gynecology. When the difficulty is primarily about the relationship, a couples therapist is the better starting point. An active suicidal crisis needs an emergency department today.

Cost and booking

Initial evaluations run 60 to 90 minutes, with time for a proper sexual history. The practice is out-of-network with all insurance plans; you pay directly and receive a superbill to submit for reimbursement. Fees are listed at out-of-network costs, and this guide explains how to check your benefits before the first visit.

Bring your current medication list with doses and dates started, and any prior antidepressant trials with the reason each was stopped. Schedule a consultation or call (646) 893-4309.

Related

Depression · Medication management · Treatment-resistant depression · Medication vs therapy vs both · Second opinions · Generalized anxiety disorder · What type of doctor treats depression · Emotional blunting on antidepressants · Antidepressants and weight gain · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · Lexapro vs Zoloft · SSRIs for teens · Stopping antidepressants · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

Stopping an antidepressant abruptly because of side effects carries relapse risk, and the weeks after any medication change deserve closer attention to mood. Suicidal thoughts without immediate crisis still warrant same-day or next-day psychiatric evaluation.

Frequently Asked Questions

How common are sexual side effects with SSRIs?

Common. When patients are asked directly with a structured questionnaire, 58% to 73% of those on SSRIs or venlafaxine report sexual dysfunction (Montejo, 2001), and a 2009 meta-analysis found 25.8% to 80.3% across serotonergic antidepressants. Label figures are much lower because they rely on spontaneous reports.

Which antidepressants have the fewest sexual side effects?

Bupropion has the most consistent evidence: it did not differ from placebo in a 2009 meta-analysis and carried the lowest prevalence (22% to 25%) in a US primary care study of 6,297 adults. Mirtazapine and vortioxetine also carry lower rates than SSRIs in most data, though mirtazapine's results vary across studies. Each has other trade-offs.

Do antidepressant sexual side effects go away on their own?

Sometimes in the first weeks, and after that usually not. The authors of the largest switching trial summarized the literature as "does not resolve in most patients." About a third of psychiatrists in a 2019 Spanish study chose to wait, which is reasonable early on. If the problem persists, discuss dose, switching, or an add-on medication.

Can I take Viagra with my antidepressant?

For men with erectile symptoms, sildenafil was effective in a 2003 JAMA trial: 54.5% improved versus 4.4% on placebo, with depression staying in remission. A Cochrane review found sildenafil and tadalafil both helped men. The use is off-label and needs cardiovascular and drug-interaction screening. In women, a 2008 trial found a modest benefit and the evidence remains uncertain.

What is post-SSRI sexual dysfunction?

PSSD refers to sexual symptoms, most often genital numbness, weak or pleasureless orgasm, and low desire, that persist after an SSRI or SNRI is stopped. Reviews in 2017 and 2018 concluded that it exists but its frequency is unknown, and in 2019 the European Medicines Agency required SSRI and SNRI labels to mention it. Evaluation starts by excluding other causes.

Should I stop my antidepressant if it is affecting my sex life?

Not on your own. Stopping abruptly risks relapse and, with shorter-acting drugs, discontinuation symptoms. Bring the problem to your prescriber, who can lower the dose, switch to bupropion or vortioxetine, add bupropion, or prescribe a PDE5 inhibitor, each with trial evidence behind it. The goal is an antidepressant that works and intact sexual function.

Sources

1. Montejo AL, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62 Suppl 3:10–21. PMID 11229449
2. Montejo AL, et al. A real-world study on antidepressant-associated sexual dysfunction in 2144 outpatients: the SALSEX I study. Arch Sex Behav. 2019;48(3):923–933. PMID 30790204
3. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266. PMID 19440080
4. Clayton AH, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–366. PMID 12000211
5. Reichenpfader U, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37(1):19–31. PMID 24338044
6. Jacobsen PL, et al. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–378. PMID 26575433
7. Taylor MJ, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;(5):CD003382. PMID 23728643
8. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514–1516. PMID 7573593
9. Thase ME, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974–981. PMID 16086611
10. U.S. Food and Drug Administration. WELLBUTRIN XL (bupropion hydrochloride extended-release tablets) prescribing information, 2017. accessdata.fda.gov
11. Jacobsen PL, et al. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036–2048. PMID 26331383
12. Clayton AH, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62–67. PMID 14744170
13. Nurnberg HG, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289(1):56–64. PMID 12503977
14. Nurnberg HG, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395–404. PMID 18647982
15. Reisman Y. Sexual consequences of post-SSRI syndrome. Sex Med Rev. 2017;5(4):429–433. PMID 28642048
16. Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6(1):29–34. PMID 28778697
17. Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125–134. PMID 29733030
18. European Medicines Agency, Pharmacovigilance Risk Assessment Committee. PRAC recommendations on signals adopted at the 13–16 May 2019 PRAC meeting (EMA/PRAC/265212/2019): SSRIs and SNRIs, persistent sexual dysfunction after drug withdrawal. ema.europa.eu